Riskpilot← Back to searchSign inGet full accessAOP Orphan Pharmaceuticals Sweden AB
ABActiveOrg 5591698708Köpsvängen 16Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201810-19 employees
Revenue 2024
SEK 31,3M
+10% vs 2023
EBITDA margin
5.7%
+120% vs 2023
Equity ratio
46.6%
Financial strength
Net profit 2024
SEK 1,4M
+152% vs 2023
| Revenue | SEK 31,3M | +10% |
| EBITDA | SEK 1,8M | +120% |
| Net profit | SEK 1,4M | +152% |
| Total assets | SEK 8,5M | +17% |
| Equity | SEK 3,9M | +53% |
| Employees | — | — |
Legal name
AOP Orphan Pharmaceuticals Sweden AB
Org number
5591698708
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
3 september 2018
Share capital
SEK 50 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva konsultativ verksamhet inom ekonomi och finans samt kapitalförvaltning samt därmed förenlig verksamhet.
Address
Köpsvängen 16
Email
office.se@aoporphan.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 18 772 | 27 648 | 27 450 | 28 371 | 31 307 |
| Staff expenses | — | — | — | −15 991 | −17 599 |
| EBITDA | 436 | 972 | 885 | 815 | 1 790 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 436 | 972 | 885 | 815 | 1 790 |
| Net financials | −24 | −12 | −63 | −64 | 3 |
| Profit before tax | 412 | 959 | 822 | 751 | 1 793 |
| Tax | −100 | −220 | −270 | −211 | −435 |
| Net profit | 312 | 739 | 552 | 540 | 1 359 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 208 | 14 213 | 10 281 | 7 211 | 8 461 |
| Equity | 754 | 1 499 | 2 064 | 2 587 | 3 946 |
| Long-term debt | 1 844 | 1 844 | 0 | — | — |
| Short-term debt | 3 610 | 10 870 | 8 217 | 4 623 | 4 515 |
| Total debt | 5 454 | 12 714 | 8 217 | 4 623 | 4 515 |
EBITDA margin
5.7%
This company
15.8%
Market median
-64% vs market
20202024
Equity ratio
46.6%
This company
38.2%
Market median
+22% vs market
20202024
Return on equity
34.4%
This company
18.4%
Market median
+87% vs market
20202024
Net profit margin
4.3%
This company
8.1%
Market median
-47% vs market
20202024
Asset turnover
3.70×
This company
1.12×
Market median
+230% vs market
20202024
Debt / equity
1.14×
This company
0.62×
Market median
-84% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SM Chief Executive Officer | Chief Executive Officer | 2023 |
SA Chief Auditor | Chief Auditor | 2024 |
| Former (3) | ||
CA Chief Executive Officer | Chief Executive Officer | 2023 – 2023 |
PN Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
BY Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2026 | |
| Former (2) | ||
| Deputy Board Member | 2020 – 2026 | |
| Board of Directors | 2023 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AOP ORPHAN PHARMACEUTICALS GMBH
AOP Orphan Pharmaceuticals Sweden AB (this company)Board members of AOP Orphan Pharmaceuticals Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christian Anders Feinberg | Chief Executive Officer | 0 companies |
| Sofia Maria Opitz | Chief Executive Officer | 0 companies |
| Stéphanie Anna Chantal Ljungberg | Chief Auditor | 0 companies |
| Per-Åke Niska | Chief Executive Officer | 0 companies |
| Bettina Yvonne Blosse | Chief Executive Officer | 0 companies |
| Nicola Zancan | Deputy Board Member | 0 companies |
| Bernhard Nachbaur | Deputy Board Member | 0 companies |
| Andreas Steiner | Board of Directors | 0 companies |